On 25 November 2025, Sanofi entered into a share purchase agreement to sell a 70% stake in the company operating its Lüleburgaz pharmaceutical manufacturing facility to Fareva, a world leader in industrial subcontracting for the pharmaceuticals, cosmetics, and industrial & household sectors. Sanofi will retain a 30% minority stake in the company.
The Lüleburgaz facility is one of Türkiye’s leading pharmaceutical manufacturing sites, with significant production capacity and export capabilities. The transaction is expected to close upon completion of customary regulatory approvals, including clearance from the Turkish Competition Authority.
Paksoy is pleased to announce that a team consisting of partner Stéphanie Beghe Sönmez, along with counsel Zeynep Toma and associates Selen Toma and Cansın Taner, is acting as counsel to Sanofi on this transaction.
Share
Related persons
You can contact us for detailed information.



Legal Information
This briefing is for information purposes; it is not legal advice. If you have questions, please call us. All rights reserved.
You May Be Interested In
5 January 2026
We are pleased to announce the promotion of Sabri Kaya to Counsel, effective as of 1 January 2026
We extend our congratulations to Sabri Kaya on his well-deserved promotion to Counsel.
5 January 2026
We are pleased to announce the promotion of Doğuhan Uygun and Zekican Samlı to Partner, effective as of 1 January 2026
We extend our congratulations to Doğuhan Uygun and Zekican Samlı on their well-deserved promotion to Partner.
29 December 2025
Paksoy advised GAMA Enerji on the sale of İç Anadolu Natural Gas Combined Power Plant to SOCAR
Paksoy advised GAMA Enerji on the sale of İç Anadolu Natural Gas Combined Power Plant to SOCAR
16 December 2025
We are recognised as Tier 1 in Dispute Resolution and Tier 2 in Arbitration by Benchmark Litigation in Türkiye
We are recognised as Tier 1 in Dispute Resolution and Tier 2 in Arbitration by Benchmark Litigation in Türkiye.
